IN SWEDISHNordForsk, a pan-Nordic financier, has provided € 2.3 million to accelerate the introduction of Stockholm3 in the Nordic countries. The project is a collaboration between Karolinska Institutet and care providers and research institutions in Sweden, Norway, Denmark and Finland and lasts for two years. More information is available on Nordforsk’s website.
Stockholm3 is a blood test that finds twice as many men with aggressive prostate cancer and at the same time reduces the number of unnecessary tissue samples by half compared to current practice. The Stockholm3 test has been tested on nearly 60,000 men and is based on research conducted at Karolinska Institutet
